open access

Ahead of print
Research paper
Published online: 2021-06-16
Get Citation

Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving breast cancer patients: A single-centre retrospective observational study

Agnieszka Jagiełło-Gruszfeld, Anna Niwińska, Wojciech Michalski, Katarzyna Pogoda, Roman Dubiański, Michał Kunkiel, Izabela Lemańska, Renata Sienkiewicz, Anna Górniak, Ewa Kosakowska, Zbigniew Nowecki
DOI: 10.5603/OCP.2020.0048

open access

Ahead of print
ORIGINAL ARTICLE
Published online: 2021-06-16

Abstract

A retrospective observational study of the outcomes of darbepoetin alfa treatment for chemotherapy-induced anaemia in breast cancer patients was conducted. A group of 152 patients treated during 13 months in one oncology centre was assessed. Ninety-eight patients (64.5%) received perioperative chemotherapy, and 54 patients (35.5%) received palliative chemotherapy. The results of treatment with darbepoetin alfa were analysed by age ( < 65 vs. ≥ 65 years), the aim of chemotherapy (perioperative vs. palliative), and body mass index ( < 25 vs. 25–29 vs. 30 and more). The effectiveness of the therapy was estimated at 80.9% (95% CI: 74.7–87.2%). Significantly higher effectiveness of ESA was found in patients treated perioperatively compared to patients treated for metastatic breast cancer (85.7% vs. 72.2%, p = 0.043). There were no differences in the effectiveness of ESA depending on age and BMI. No serious ESA-related adverse events were observed.

Abstract

A retrospective observational study of the outcomes of darbepoetin alfa treatment for chemotherapy-induced anaemia in breast cancer patients was conducted. A group of 152 patients treated during 13 months in one oncology centre was assessed. Ninety-eight patients (64.5%) received perioperative chemotherapy, and 54 patients (35.5%) received palliative chemotherapy. The results of treatment with darbepoetin alfa were analysed by age ( < 65 vs. ≥ 65 years), the aim of chemotherapy (perioperative vs. palliative), and body mass index ( < 25 vs. 25–29 vs. 30 and more). The effectiveness of the therapy was estimated at 80.9% (95% CI: 74.7–87.2%). Significantly higher effectiveness of ESA was found in patients treated perioperatively compared to patients treated for metastatic breast cancer (85.7% vs. 72.2%, p = 0.043). There were no differences in the effectiveness of ESA depending on age and BMI. No serious ESA-related adverse events were observed.

Get Citation

Keywords

chemotherapy-induced anaemia; breast cancer; darbepoetin alfa; erythropoietin-stimulating agents

About this article
Title

Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving breast cancer patients: A single-centre retrospective observational study

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Research paper

Published online

2021-06-16

DOI

10.5603/OCP.2020.0048

Keywords

chemotherapy-induced anaemia
breast cancer
darbepoetin alfa
erythropoietin-stimulating agents

Authors

Agnieszka Jagiełło-Gruszfeld
Anna Niwińska
Wojciech Michalski
Katarzyna Pogoda
Roman Dubiański
Michał Kunkiel
Izabela Lemańska
Renata Sienkiewicz
Anna Górniak
Ewa Kosakowska
Zbigniew Nowecki

References (30)
  1. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008; 3(1): 200–207.
  2. Aapro MS. Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Oncologist. 2008; 13 Suppl 3: 1–3.
  3. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007; 131(5): 702–707.
  4. Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg. 2009; 208: 931–937.
  5. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40(15): 2293–2306.
  6. Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004; 15(6): 979–986.
  7. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91(12): 2214–2221.
  8. Radziwon P, Krzakowski M, Kalinka-Warzocha E, et al. Anemia in cancer patients — Expert Group recommendations. Oncol Clin Pract. 2017; 13(202): 210.
  9. Aapro M, Beguin Y, Bokemeyer C, et al. ESMO Guidelines Committee, ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv96–iv9iv110.
  10. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06 14_QuickReference_5x7.pdf.
  11. htps://www.ema.europa.eu/en/documents/product-information/aranesp-epar-product-information_pl.pdf.
  12. Moebus V, Jackisch C, Schneeweiss A, et al. AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013; 105(14): 1018–1026.
  13. Sabir S, Khan YH, Khatoon M, et al. Effect of Erythropoiesis Stimulating Agents on Clinical Outcomes in Breast Cancer Patients: A Systematic Review of Randomised Controlled Trials. J Coll Physicians Surg Pak. 2020; 30(3): 292–298.
  14. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91(19): 1616–1634.
  15. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13(12): 2886–2894.
  16. Link H. Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia. Breast Care (Basel). 2019; 14(2): 93–98.
  17. Van Belle S, Karanikiotis C, Labourey JL, et al. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study. Curr Med Res Opin. 2011; 27(5): 987–994.
  18. Vansteenkiste J, Pirker R, Massuti B, et al. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94(16): 1211–1220.
  19. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007; 21(4): 627–632.
  20. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997; 15(3): 1218–1234.
  21. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26(10): 1619–1625.
  22. Massa E, Madeddu C, Lusso MR, et al. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol. 2006; 57(2): 175–182.
  23. Kurtz JE, Soubeyran P, Michallet M, et al. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Onco Targets Ther. 2016; 9: 6689–6693.
  24. Berbec NM, Stanculeanu DL, Badelita NS, et al. APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania. Memo. 2018; 11(2): 144–151.
  25. https://www.mp.pl/interna/chapter/B16.IV.24.21.
  26. Welsh L, Panek R, Riddell A, et al. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br J Cancer. 2017; 116(1): 28–35.
  27. Meybohm P, Herrmann E, Steinbicker AU, et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient’s outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg. 2016; 264: 203–211.
  28. Aapro M, Moebus V, Nitz U, et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Ann Oncol. 2015; 26(4): 688–695.
  29. Chavez-MacGregor M, Zhao H, Fang S, et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 2011; 117(16): 3641–3649.
  30. Leyland-Jones B, Bondarenko I, Nemsadze G, et al. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. J Clin Oncol. 2016; 34(11): 1197–1207.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl